Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.

Abstract

BACKGROUND:

This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan in combination with pazopanib in patients with advanced solid tumours.

METHODS:

Stage I of this study was to determine whether there was an impact of pazopanib on topotecan exposure. In stage II, the MTD and safety profile of oral topotecan given weekly on days 1, 8 and 15 in a 28-day cycle; or daily-times-five on days 1-5 in a 21-day cycle, both in combination with daily pazopanib, were explored.

RESULTS:

In total, 67 patients were enroled. Pazopanib co-administration caused a substantial increase in exposure to total topotecan (1.7-fold) compared with topotecan alone, which is considered clinically relevant. Topotecan had no effect on pazopanib concentrations. Safety findings were consistent with the known profile of both agents. There were three drug-related deaths, liver failure, tumour haemorrhage and myelosuppression. Two patients experienced dose-limiting toxicities (DLTs; hand-foot syndrome, myelosuppression and diarrhoea) on the weekly topotecan schedule and four patients experienced DLTs (myelosuppression) on the daily-times-five topotecan schedule. When combined with pazopanib, 800 mg daily, the recommended doses for oral topotecan are: 8 mg weekly and 2.5 mg daily-times-five. Seven of eight patients with partial response had platinum-resistant ovarian cancer. In addition, 54% of patients had stable disease with 22% stable for 6 months.

CONCLUSIONS:

Total topotecan exposure is 1.7-fold higher when co-administered with pazopanib. Both schedules of administration were tolerated and would permit further evaluation, especially the weekly schedule.

• Authors: B Milojkovic Kerklaan, M P J Lolkema, L A Devriese, E E Voest, A Nol-Boekel, M Mergui-Roelvink, M Langenberg, K Mykulowycz, J Stoebenau, S Lane, P Legenne, P Wissel, D A Smith, B J Giantonio, J H M Schellens, P O Witteveen
• Journal: British journal of cancer (Br J Cancer) Vol. 113 Issue 5 Pg. 706-15 (Sep 01 2015) ISSN: 1532-1827 [Electronic] England
• PMID: 26291057 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Indazoles
• Pyrimidines
• Sulfonamides
• Topotecan
• pazopanib

Topics

• Administration, Oral
• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics, therapeutic use, toxicity)
• Female
• Humans
• Indazoles
• Male
• Maximum Tolerated Dose
• Middle Aged
• Ovarian Neoplasms (drug therapy, pathology)
• Pancreatic Neoplasms (drug therapy, pathology)
• Pyrimidines (administration & dosage)
• Sulfonamides (administration & dosage)
• Topotecan (administration & dosage)
• Treatment Outcome
• Young Adult